Experts discuss the integration of ocular toxicity management in solid tumor care, focusing on antibody-drug conjugates and their impact on treatment.
Integrating Ocular Toxicity Management into Routine Care for Solid Tumor Patients Receiving Treatment with ADCs
Ocular toxicities from cancer treatments present complexities; understanding symptoms and timely ophthalmology involvement is crucial for effective management.
Experts discuss the integration of ocular toxicity management in solid tumor care, focusing on antibody-drug conjugates and their impact on treatment.
EP. 4: Defining Grade 1 Ocular Toxicities and When to Prioritize Baseline Eye Exams While Using ADCs
Ophthalmologists discuss the importance of grading dry eye symptoms and the necessity of eye exams before starting certain treatments.
Medical oncologists explore the importance of ophthalmology referrals for ocular toxicities, emphasizing collaboration for optimal patient care.
Explore the latest insights on antibody-drug conjugates in oncology and their associated ocular toxicities, enhancing patient care and treatment outcomes.
Experts discuss the challenges of ocular toxicities in oncology, emphasizing collaboration and the importance of preservative-free eye drops for patient care.
Experts discuss the challenges of ocular toxicities in oncology, emphasizing collaboration and the importance of preservative-free eye drops for patient care.
Explore the roles of optometrists and ophthalmologists in managing ocular toxicities, ensuring timely patient care and effective treatment strategies.
Experts discuss the alignment of clinical trial data with real-world experiences in managing ocular toxicities in cancer treatments.
Experts discuss the importance of monitoring ocular toxicities in cancer treatment, emphasizing timely interventions and effective communication between oncologists and ophthalmologists.
Explore the differences in supportive care for antibody-drug conjugates and their impact on ocular health in patients.
Oncology care thrives on teamwork, emphasizing patient education and communication to manage treatment-related ocular toxicities effectively.
Advertisement
Advertisement
Trending on OncLive
1
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
2
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
5